Received a 483
See where similar pressure areas may still be building before repeat issues demand more time and attention.
FDA inspection intelligence for pharmaceutical, device, and regulated manufacturers
Which CFR areas are gaining inspection attention?
483Radar helps quality, regulatory, and compliance teams understand where inspection attention may be increasing, what that could mean if FDA inspects, and where limited review resources may deserve focus first.
Each monthly spot includes a short qualification call, live category-level profile setup, a fixed-date benchmark analysis, and delivery of both an Executive Report and deeper Technical Dossier.
No internal system access required to begin.
No internal system accessCustom blindspot-style reportUp to 5 selected teams/month
Limited monthly report spots
Claim one of this month's 5 complimentary report spots.
Problem
Most teams see the warning signs in retrospect.
483 observations, import alerts, and sector-level inspection patterns are visible in external data before they appear internally. A structured outside-in view gives quality and regulatory leaders a way to see where FDA inspection pressure is building — before it shows up in the internal record.
How the monthly spots work
What happens after you request a spot
01
Request a spot
Submit your details and operating category. We review requests manually and select up to 5 teams per month.
02
Short qualification call
If there is a fit, we schedule a brief call to understand your context, answer questions, and complete a simple category-level profile live.
03
Fixed-date benchmark analysis
Using your profile, we generate a dated 1/1/2026 report from the platform. This gives your team a stable reference point to assess whether the signals, pressure areas, and priorities reflected in the report align with what you know from experience.
04
Receive both report formats
You receive an Executive Report for leadership review and a Technical Dossier for deeper analysis and working-level discussion.
Best fit
Best fit for teams that need external inspection context.
Received a warning letter
Understand where FDA attention may remain concentrated as you work through response and remediation.
Preparing for a new inspection
Bring an external signal view into your readiness process before FDA is back on site.
Need to prioritize limited resources
Focus time and review effort on the areas most likely to matter, instead of spreading attention too thin.
What selected teams receive
The output is designed to surface pressure, prioritization, and momentum.
External attention patterns
A structured view of where inspection pressure may be increasing across relevant operational themes.
Blindspot-style prioritization
A ranked view intended to help leaders identify which categories may deserve closer attention first.
Change and momentum context
Where relevant, the analysis can show whether pressure appears stable, rising, or shifting over time.
Leadership-ready summary
A concise report and live review call built to support internal discussion and next-step review.
Apply now
See what's building around your operation.
The application takes under 3 minutes. No internal system access or validated data required to begin.